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ABSTRACT  
Ethnopharmacological relevance 
Casearia sylvestris Sw. is widely used in popular medicine to treat conditions 
associated with pain.  
Aim of the study 
The present study investigated the influence of hydroalcoholic crude extract of Casearia 
sylvestris (HCE-CS) and contribution of pro-resolving mediators on mechanical 
hyperalgesia in a mouse model of chronic post-ischemia pain (CPIP).  
Methods and results 
Male Swiss mice were subjected to ischemia of the right hind paw (3 h), then 
reperfusion was allowed. At 10 min, 24 h or 48 h post-ischemia/reperfusion (I/R), 
different groups of animals were treated with HCE-CS (30 mg/Kg, orally [p.o]), 
selected agonists at the proresolving receptor ALX/FPR2 (natural molecules like 
resolvin D1 and lipoxin A4 or the synthetic compound BML-111; 0.1-1 µg/animal) or 
vehicle (saline, 10mL/Kg, s.c.), in the absence or presence of the antagonist WRW4 (10 
µg, s.c.). Mechanical hyperalgesia (paw withdrawal to von Frey filament) was asseseed 
together with histological and immunostainning analyses. In these settings, pro-
resolving mediators reduced mechanical hyperalgesia and HCE-CS or BML-111 
displayed anti-hyperalgesic effects which was markedly attenuated in animals treated 
with WRW4. ALX/FPR2 expression was raised in skeletal muscle or neutrophils after 
treatment with HCE-CS or BML-111.  
Conclusion 
These results reveal significant antihyperalgesic effect of HCE-CS on CPIP, mediated at 
least in part, by the pathway of resolution of inflammation centred on the axis 
modulated by ALX/FPR2. 
Key words: Casearia sylvestris; Salicaceae; Chronic post-ischemia pain; Inflammation; 
ALX/FPR2. 
 
1. Introduction  
We have previously reported that the hydroalcoholic crude extract from Casearia 
sylvestris Sw. (HCE-CS) exert several actions on specific responses of pain and 
inflammation. Antinociceptive actions were evident in animal models of nociceptive, 
inflammatory and immune mediated pain (De Mattos et al., 2007); furthermore, the 
HCE-CS was also endowed with anti-inflammatory properties in the model of 
carrageenan-paw edema in mice, as well as in pleurisy model in rats reducing neutrophil 
recruitment and nitrite/nitrate production in pleural exsudate (Albano et al., 2013).  
The Casearia sylvestris specie was recently related to the family of Salicaceae 
(Ferreira et al., 2011) and contains phytochemicals from different classes of medicinal 
interest such as sesqui- (Bou et al., 2013) and diterpenes (Meesakul et al., 2016). 
Among this last class, Dos Santos and colleagues (Dos Santos et al., 2010) recently 
reported the isolation of five new compounds, termed casearins and casearvestrins.  
Together with other coumpounds, casearins can be able to inhibit the activity of 
phospholipase A2 (PLA2) (Borges et al., 2000; Borges et al., 2001), which seems to be a 
property in agreement with the ethnopharmacological use of the plant in popular 
medicine for the treatment of wounds and ulcers or against snake bites (Ferreira et al., 
2011). Collectively, these results raise the possibility that the plant could exert 
antinociceptive and anti-inflammatory effects based on mechanisms relied on resolution 
of inflammation pathways in other unexplored models of pain and inflammation, since 
PLA2 is also targeted by others pro-resolving mediators. 
The resolution of inflammation is a programmed response from the organism to 
enable the end of the inflammatory process and ensure that the affected organ goes back 
to its pre-inflammatory settings and function (Perretti, 2015). Specific pro-resolving 
mediators and pathways are operative to enact resolution including those centred on 
annexin A1 (AnxA1) and lipoxin A4 (LXA4) (Cash et al., 2014). Accumulating 
evidence from diverse animal models indicate modulatory properties for pro-resolving 
mediators on nociception (Pei et al., 2011; Pierretti et al., 2001) and hyperalgesia 
(Abdelmoaty et al., 2013; Hu et al., 2012; Huang et al., 2011), through mechanisms that 
involve modulation of the expression of transcriptional factors and cytokines (Liu et al., 
2016; Sun et al., 2012; Wang et al., 2014). Similarly, pivotal roles for the endogenous 
local signals that govern resolution to impact on pain processes have already defined 
(for review: Serhan, 2008). Against this background, we speculated a possible 
synergism of action for both HCE-CS and pro-resolving mediators on pain associated 
with inflammatory processes, the main example here being chronic post-ischemic pain 
(CPIP) typical of the Complex Regional Pain Syndrome-Type I (CRPS-I). 
CRPS-I model is able to faithfully reproduce many of the symptoms related to 
this syndrome in humans such as hyperalgesia, edema, vasomotor dysfunction and 
trophic changes (Laferrière et al., 2008). Using this model, after induction of ischemia 
and reperfusion (I/R) in the hindpaw of animals, is possible to evaluate an initial phase 
of paw edema and inflammatory pain (up to 3 days after reperfusion) followed by a 
form of neuropatic pain (from 7 to 21 days after reperfusion) (Martins et al., 2013; 
Millecamps et al., 2010). Studies have elucidated few aspects of the histology of the 
skin and microvasculature of the paw tissues after I/R (Coderre & Bennett, 2010; 
Millecamps, 2010), yet joints and skeletal muscle have not been investigated, both in 
the absence or presence of specific pharmacological treatments. Herein, we aimed to 
investigate the effect of HCE-CS or pro-resolving mediators on mechanical 
hyperalgesia observed in CRPS-I through behavioral and histological analysis, as well 
as establish a possible influence of resolution of inflammation pathways to the effects of 
the plant extract. 
 
2. Material and methods 
2.1 Preparation and characterization of the hydroalcoholic crude extract of Casearia 
sylvestris (HCE-CS). 
Extract was obtained from leaves of the plant collected at the botanical Horto at the 
campus of University Southern Santa Catarina (UNISUL), in the municipality of 
Tubarão, Santa Catarina, Brazil (latitude 28º28'00" south and longitude 49º00'25" west) 
and prepared as previously described (Albano et al., 2013) and the plant was identified 
by direct comparison with a voucher specimen (SRS-174) deposited at the herbarium 
Laelia Purpurata (SRS) at this university. Concentrated HCE of Casearia sylvestris 
was then stored in a desiccator until the moment of use. 
The HCE-CS was analyzed by ultra-high performance liquid chromatography 
coupled to diode array detection (UHPLC-DAD) using water (A) and acetonitrile (B) as 
eluents and a solid core C18 chromatographic column (Kinetex C18, 150 x 2.1 mm, 2.6 
μm, 100 Å) according to the method previously developed (Bueo et al., 2015). A 
volume of 2 μL of each sample and the points of the analytical curve were injected in 
triplicate under the following elution gradient: 10 to 25% of B for 15 min and then 25 to 
90% of B for 20 min, remaining in this condition for 5 min. A method for 
reconditioning was incorporated so that it returned to the initial condition in 2 min and 
remained in that condition for another 3 min, for a total time of 45 min. The flow rate 
was 0.4 mL/min, with column temperature at 35°C, detection range 200-800 nm and 
plotting the chromatograms at 235 nm. 
Identification of the main compounds was achieved by ultra-high performance 
liquid chromatography coupled to mass spectrometry in positive mode (UHPLC-ESI-
MS, Amazon SL, Bruker Daltonics) with the aid of previously isolated standards and 
information from literature. The chromatographic conditions were the same as described 
above. The ion trap operated in enhanced resolution mode with a capillary potential of 
140 V. The capillary temperature was set at 300 °C with a nebulizer pressure of 30 psi 
and a dry gas flow of 8 L min−1.  
From an analytical curve based on caseargrewiin F was possible to determine the 
concentration of total casearins in the HCE-CS. For each sample, the total of casearins 
content was calculated by summing the areas of all peaks corresponding to this 
compounds in the chromatograms and expressing the results as a function of 
caseargrewin F. It is important to note that, for such substances, the spectra in the 
ultraviolet region have a characteristic peak at 225-235 nm (Fig. 1A). The total 
casearins content was 18.6 mg/g (or 1.86% m/m), with a standard deviation of 0.8% 
(Fig. 1B). 
 
 
Fig. 1. Chromatographic profile of HCE-CS. The peaks marked with (*) correspond to 
unindentified casearins.The following casearins were identified by UHPLC-ESI-MS (1) 
casearin L/A ([M+Na]+ = 557,25 m/z); (2) casearin D ([M+Na]+ = 571,30 m/z); (3) 
caseargrewiin F and casearin K/Q ([M+Na]+ = 527,28 and 585,26 m/z, respectively); (4) 
casearin S ([M+Na]+ = 497,28 m/z); (5) casearin X ([M+Na]+ = 555,29 m/z); (6) 
casearin B/T ([M+Na]+ = 599,30 m/z); (7) casearin J ([M+Na]+ = 585,32 m/z); (8)  
casearvestrin B  ([M+Na]+ = 541,29 m/z); (9) casearin O/N ([M+Na]+ = 627,32 m/z); 
(10) casearin E ([M+Na]+ = 613,36 m/z).  
 
2.2. Animals 
All experiments were conducted using male Swiss or C567BL-6 mice (wild type or 
knock out for AnxA1), weighting 25–35 g, housed at 22 ± 2 oC, under a 12 h light/12 h 
dark cycle (lights on at 06:00 h) and with free access to food and water. Mice were 
acclimated to the Laboratory of Experimental Neuroscience (Lanex), at 
UNISUL/Brazil-SC for at least 1 h before the tests that were carried out between 08:00 
and 12:00 a.m. Animals were used only once throughout the experiments. All animal 
care and experimental procedures were carried out in accordance with the National 
Institutes of Health Animal Care Guidelines (NIH publications No. 80-23) and were 
approved by the Ethics Committee for Animal Use (CEUA)-UNISUL, under protocol 
number 13.036.4.03.IV. The number of animals and intensity of noxious stimuli used 
were the minimum necessary to demonstrate the consistent effects of treatments. 
Experimenters were blinded to treatment conditions. 
 
2.3. Hindpaw ischemia and reperfusion. 
The animal model of CPIP was generated following exposure to prolonged hind paw 
I/R and was carried out according to the procedure described for rats (Coderre et al., 
2004) and adapted for mice (Millecamps et al., 2010). Mice were anesthetized over a 3 
h period with a bolus (7%, 0.6 ml/kg, i.p.) of chloral hydrate and 20% of the initial 
volume at the end of the first and second hour. After induction of anesthesia, an elastic 
 -ring for  races ( l stic o Ligadura 000-1237, Uniden, SP, Brazil) with 1.2 mm 
internal diameter was placed around the right hind limb just proximal to the ankle joint. 
The O-rings were selected to provide a tight-fit that produced ischemia. They were left 
on the limb for 3 h as initially described with larger O-rings. The O-ring was always 
positioned at a point on the limb just proximal to the medial malleolus. Sham mice were 
subjected to the same procedure except that the O-ring was cut so that it only loosely 
surrounded the ankle and did not occlude blood flow to the right hind paw (Martins et 
al., 2013). 
 
2.4. Assessment of mechanical hyperalgesia in Swiss mice. 
The characteristic mechanical hyperalgesia of CPIP induced by the I/R procedure was 
assessed using von Frey monofilaments (VFH, Stoelting, Chicago, USA), measured as 
the frequency of response (in percentage) of paw withdrawal from the tested animals, to 
10 applications of a von Frey filament with a force of 0.6 g. The test was performed 
using a platform (70 cm x 40 cm), which consists of a wire screen mesh of 6 mm to 
facilitate the application of the filament on the ventral surface of the hind paw of the 
animals. Mice were individually placed in an observation chamber made of acrylic (9 
cm x 7 cm x 11 cm), which had no bottom and was covered. The following criteria for 
applying the mechanical stimuli were considered: a) application was made 
perpendicularly to the plantar surface with sufficient pressure to provide the curvature 
of the filament, obtaining the total pressure, b) the animals were assessed when all four 
paws were accommodated on the screen, c) the withdrawal response was considered 
positive when the animal completely removed its paw from the surface of the screen. 
The mechanical hyperalgesia was evaluated before the I/R (basal values) and at 
different times after treatment.  
In a first set of experiments, we evaluated the possible contribution of pro-
resolving mediators in synergism with HCE-CS. To this end, 10 min, 24 and 48 h after 
induction of I/R the animals were treated with different doses of the mediators resolvin 
D1 (RvD1, 0.1 µg, endovenously [e.v.]), an agonist for the GPR32 and ALX/FPR2 
receptors or 15-epi-LXA4 (a LXA4 stable analogue, 1 µg, e.v.) and BML-111 (a 
synthetic analog of the LXA4; doses of 0.1, 0.3 or 1 µg/animal, subscutaneously [s.c.]), 
agonists for the ALX/FPR2 receptor. Parameters of mechanical hyperalgesia and adema 
were assessed up to 72 hours after the I/R procedure. 
In a second set of experiments, animals were treated after induction of CPIP 
(same period of time as in first experiments) with vehicle (5% tween 80, 10 mL/Kg, 
p.o.), HCE-CS (30 mg/Kg, p.o.), dexamethasone (0.5 mg/Kg, p.o.) or BML-111 (1 
µg/animal, s.c.). Mechanical hyperalgesia was assessed 49 h after the I/R procedure.  
Finally, to assess the possible involvement of endogenous ALX/FPR2 in the 
antihyperalgesic effect induced by HCE-CS or pro-resolving mediators in this model, 
48 h after I/R, two groups of animals were treated with vehicle (5% tween 80, 10 
mL/Kg, p.o.) or WRW4 (receptor antagonist, 10 µg/animal, s.c.). After 15 min, animals 
then received HCE-CS (30 mg/Kg, p.o.) or BML-111 (1 µg/animal, s.c.) and 
mechanical hyperalgesia was assessed 49 h after the I/R procedure.  
 
2.5. Functional impact of the AnxA1 pathway on CPIP. 
The role of endogenous AnxA1 pathway on CPIP was investigated by assessing 
mechanical hyperalgesia in CRPS-I model using C567BL-6 wild type (AnxA1+/+) and 
knock out (AnxA1-/-) mice, with analyses conducted at the 48 h time-point. 
 
 
2.6. Histological Analysis.  
Samples obtained from the in vivo experiments were processed according to the type of 
ex vivo analysis as described below. Since histology for skeletal muscle or joints 
(cartilage or pannus formation) had never been evaluated during the inflammatory 
phase of CRPS-I model, the samples of animal paws removed at 49 h after reperfusion.  
Samples were embedded in paraffin, cut into microtome sections (5 μm) and mounted 
on glass slides to assess the tissue changes in animals from different groups after I/R 
procedure. For muscle investigation, samples were processed for staining and analysis 
using methodolgy previously described (Norling et al., 2016; Headland et al., 2015). 
Acquired images were amplified and analysed through the ImagePro Plus® software by 
counting the number of cells present in a delimited area of 10% of the total image by 
using a tag point marker and registered as the number of cells/10% of the image. For 
cartilage and pannus assessment, images encompassing the joint areas of the tarsus 
(tarsus-navicular and navicular-cuneiform-proximal metatarsal) and metatarsal areas 
(cuboid-metatarsal joint, intermediate region of the metatarsal and phalangeal-
metatarsal joint) were evaluated for the pannus by the presence along the synovial 
structures (grade 0: no pannus; grade 1: pannus presence along the synovium, grade 2: 
marginal pannus and invading the synovium). Finally, cartilage erosion was assessed 
from images encompassing the tarsus-navicular area of the phalangeal-metatarsal joint 
analysed by using the ImageJ® software, in which images were divided within the 
channels of different colours (red, green and blue) and images were selected from the 
channel that best represented the positive and negative stainning in the samples. A 
colouring threshold was applied to the image of that channel, tracing the total cartilage 
area from which the software removed the erosion area (without staining), resulting in 
the percentage of the remaining cartilage area without erosion. 
2.7. Characterization of cell types in the inflammatory infiltrate. 
Given that the one of the most accentuated phenomen observed during inflammatory 
phase is the edema (with plasma and cell extravasation from the vessel), histological 
analyses in the hind paw of the animals subjected to I/R-induced injury also examined 
the type of inflammatory cell present in the infiltrate, 49 h after paw reperfusion 
according to techniques previously registered (Leinster et al., 2012). This evaluation 
was performed using the immunofluorescence technique with samples of hind paws of 
animals belonging to different treatment groups, which were embedded in paraffin, cut 
into microtome sections (5 μm) and mounted on glass slides with subsequent 
rehydration. Antigen retrieval was performed in citrate buffer (pH 6.0) at 94°C for 30 
min, followed by incubation in hydrogen peroxide solution (0.3%) to block endogenous 
peroxidases. To identify macrophages or lymphocytes in cell infiltrates, samples were 
incubated overnight with primary antibodies against CD68 (Zymed, 1:100) or CD3 
(Santa Cruz, 1:200), respectively. An antibody diluent was added to the negative control 
group in this stage (bovine serum albumin, 1% BSA). Following addition of secondary 
antibodies conjugated with Alexa Fluor-594® or Alexa Fluor-488® (1:100), respectively, 
slides were mounted in an aqueous medium (Mauwiol). The images of FDB skeletal 
muscle area were obtained by using Olympus BH-2 microscope (Tokyo, Japan) and 
Nikon digital camera DXM1200 (Melville, NY), at 4-20X magnification.  
Analysis for the presence of neutrophil infiltrates followed the same procedure, 
with different samples incubated with primary antibodies against Ly6G (Zymed, 1:500), 
then incubated with secondary antibody conjugated with Alexa Fluor-488® (1:200). 
Samples from FDB skeletal muscle were investigated by confocal laser scanning 
microscopy (Leica TCS SP-5; Wetzlar, Germany). Control and treated samples were 
attached on slides and sealed using colorless nail polish. A Leica HCX PLAPO lambda 
63x/1.4-0.6 oil immersion objective was fitted on the fluorescent microscope. Cell 
infiltrated fluorescence was observed at 488 nm laser wavelength excitation with 
emission spectrum from 639 nm to 701 nm. The autofluorescence intensity of muscle 
cells of control and treated samples was calculated by 2 sections, 3 images each one, 
with an automatic standardized Region of Interest (ROI) where the intensity of each 
pixel was measured using the LAS-AF Lite program (Leica®). The LAS-AF Lite 
program was also used for final processing of the confocal images. 
 
2.8. Analysis of pro-resolving pathways in the antihyperalgesic effect for HCE-CS or 
BML-111. 
Paraffin embedded sections of the hindpaws of animals from different groups, 
harvested 49 h after paw reperfusion, were used for images assays for the expression of 
ALX/FPR2 or AnxA1, using double stainning immunofluorescence technique with 
methodology adapted from previous work (Patel et al., 2012). Samples of hind paws 
from animals belonging to different groups of treatment were embedded in paraffin, cut 
into microtome sections (5 μm) and mounted on glass slides with subsequent 
rehydration. Antigen retrieval was performed in citrate buffer (pH 6.0) at 94°C for 30 
min then incubated, overnight, simultaneously with specific primary antibodies against 
AnxA1 (Zymed, 1:1000) or ALX/FPR2 (Santa Cruz, 1:4000) in a humid chamber. An 
antibody diluent was added to the negative control group in this stage (bovine serum 
albumin, 1% BSA). The next day samples were simultaneosuly incubated with the 
secondary antibodies conjugated with Alexa Fluor-350® or Alexa Fluor-488®, 
respectively, to develop the reaction and then the slides were mounted in an aqueous 
medium (Mauwiol). Samples were then investigated by confocal laser scanning 
microscopy, according to described technique (De Oliveira et al., 2016).  
2.9. Statistical analysis 
The Shapiro-Wilk test was used to evaluate the normality assumption of behavioral and 
biochemical data. All variables in the present study showed a normal distribution. 
Differences among experimental groups were determined by one or two-way ANOVA 
followed by Student-Newman-Keuls Multiple Comparison or Bonferroni post hoc Test, 
respectively, when appropriate. A value of p< 0.05 was considered to be statistically 
significant. All data are presented as mean + standard error of the mean (SEM). 
 
3. Results  
3.1. Influence of pro-resolving mediators in the CRPS-I model 
Treatment of the animals with different pro-resolving mediators at 10 min, 24 and 48 h 
after I/R, reduced the mechanical hyperalgesia quantified in this model (Fig. 2). At 26 
hours after I/R, or 2 h after second treatment, RvD1 (21.7  7.6% frequency of 
response), 15-epi-LXA4 (22.7  7.3%) and BML-111 (1 µg/animal: 31.4  5.0%) 
reduced frequency of response to von Frey filaments stimulus when compared to 
vehicle treated animals (52.7  7.3% frequency of response).   
 
Fig. 2: Effect of pro-resolving agonists on experimental CRPS-I. Mice were subjected 
to I/R-induced CRPS-I (see Methods). RvD1 (100 ng, i.v.), 15-epi-lipoxin A4 (1 µg, 
i.v.) or BML-111 (100 ng to 1 µg, i.v.) were administered at 10 min, 24 and 48 h after 
reperfusion and mechanical hyperalgesia was quantified up to 72 h after reperfusion. 
Data are presented as mean ± S.E.M., n=8 (# and *= p< 0.05 vs. sham or vehicle 
groups, respectively; Two-way ANOVA followed by Tukey’s test (A) or One-way 
ANOVA followed by Bonferroni (B). 
 
3.2. WRW4 prevents antihyperalgesic effect of HCE-CS or BML-111 during 
inflammatory phase of CRPS-I model 
We then tested the treatment with HCE-CS which evoked antihyperalgesic effects (30 
mg/Kg, p.o., at 10 min, 24 and 48 h after I/R) of similar magnitude to those observed 
with BML-111 (1 µg/animal, s.c.) or dexamethasone (0.5 mg/Kg, p.o.; Fig. 3). Of 
interest, the anti-hyperalgesic effect of HCE-CS observed at 49 h was reversed by pre-
treatment of the animals with the antagonist WRW4 (Fig. 4). 
 
Fig. 3. Effect of HCE-CS in experimental CRPS-I: comparison to synthetic compounds. 
Mice were subjected to I/R-induced CRPS-I (see Methods). HCE-CS (30 mg/Kg p.o.), 
dexamethasone (dexa, 0.5 mg/Kg, i.p) or BML-111 (BML, 1 µg, s.c) were administered 
at 10 min, 24 and 48 h after reperfusion, with mechanical hyperalgesia measured 1 h 
after last administration. Data are mean ± S.E.M., n =8 (*p< 0.05 vs. vehicle controls; 
One-way ANOVA followed by Tukey’s test). 
 
3.3. AnxA1 absence did not influence mechanical hyperalgesia during the inflammatory 
phase of CRPS-I 
Data presented in Fig. 5 indicate that at 49 h after I/R the frequency of response to von 
Frey monofilaments in AnxA1+/+ animals (40.0  6.0% of response) was significantly 
higher than in sham group (10.0  4.0% of response) with values not dissimilar in 
AnxA1-/- group (36.0  6.0% of response). 
 
Fig. 4. Endogenous ALX/FPR2 mediates the control of experimental CRPS-I by HCE-
CS. Mice were subjected to I/R-induced injury (see Methods). HCE-CS (30 mg/Kg p.o., 
open circles) or BML-111 (1 µg, s.c., open triangles) were administered at 48 h post-
reperfusion, with or without the ALX/FPR2 antagonist (WRW4, 10 µg/animal, s.c.) and 
mechanical allodynia was quantified 1 h thereafter. Data are presented as mean ± 
S.E.M., n=8 (*p< 0.05 vs. vehicle controls [closed circles]; Two-way ANOVA followed 
by Bonferroni test). 
 
Fig. 5. Evaluation of functional impact of AnxA1 on mechanical hyperalgesia during 
inflammatory phase of CRPS-I model in mice. Wild type (AnxA1+/+) and knock out 
(AnxA1-/-) mice were subjected to I/R-injury (see Methods) and mechanical 
hyperlagesia was assessed at 49 h after reperfusion. Data are presented as mean ± 
S.E.M., n=8 (One-way ANOVA followed by Tukey’s test). 
 
 
 
3.4. Histological analysis for the effects of HCE-CS on tissues alterations induced by 
I/R  
As shown in Fig. 6, a massive infiltration of inflammatory cells was observed at 49 h 
after reperfusion in FDB skeletal muscle adjacent to the metatarsal region. There was a 
significant increase in the number of cells in this tissue in animals from the 
experimental group (disease, 410.3  74.6 cells) when compared to the control one 
(sham, 148.5  20.9 cells), and this effect was not influenced (Panel B) by treatment 
with the HCE-CS (470.5  67.1 cells) or selected pro-resolving mediator, BML- 111 
(385.3  46.8 cells). Regarding the characterization of the cell infiltrate, Fig. 7 shows 
that the main cell type was the neutrophils, while lymphocyte and macrophage cells 
could not be readily detected in the tissue at this time point, given that no 
immunofluorescence-staining characteristic for CD3 or CD68 markers, respectively, 
was observed (data not shown). 
 
3.5. Involvement of LXA4-ALX/FPR2 pathway in the anti-hyperalgesic effect for 
HCE-CS 
At 49 h after reperfusion, skeletal muscle of the paw subjected to I/R injury (disease) 
and neutrophils infiltrated to this tissue, did not express mediator AnxA1 (Fig. 8, Panel 
A). Besides of this, HCE-CS or BML-111 treatment increased the extent of ALX/FPR2 
receptor expression in skeletal muscle and neutrophils in relation to disease group, as 
determined by immunofluorescence (Fig. 8, Panel B). In this last experiment, 
differences between sham and disease animals could not be compared once the 
architecture of the muscle cells was significantly affected by the disease. 
Finally, no pannus formation was detected in the joints of treated animals as 
compared to the control group (sham). In a similar manner, I/R-induced injury (disease) 
did not cause cartilage erosion as monitored in a variety of joints in relation to the 
control group (sham). Both staining with Toluidine Blue (Fig. 9, panel A) or Fast Green 
+ o-Safranin (Fig. 9, panel B) were performed. 
 
Fig. 6. Inflammatory cells infiltrate the the metatarsal region of hind paws during the 
inflammatory phase of CRPS-I model in mice. Mice were subjected to I/R-induced 
CRPS-I (see Methods). Histological analysis of hind paws harvested at 49 h after 
reperfusion from sham animals or treated with HCE-CS (30 mg/Kg p.o.) or BML-111 
(1 µg, s.c.) at 10 min, 24 and 48 h after reperfusion. In quantitative analysis data are 
presented as mean ± S.E.M., n=8 (One-way ANOVA followed by Tukey’s test). 
 
Fig. 7. Neutrophils are the main cell type inflitrating the metatarsal region of hind paws 
during the inflammatory phase of CRPS-I model in mice. Mice were subjected to I/R-
injury and immunfluorescence analysis (Ly6G for neutrophils; see Methods) was 
conducted in hind paws harvested at 49 h after reperfusion from animals belonging to 
the sham or disease groups. 
 
Fig. 8. Over-expression of ALX/FPR2 but not AnxA1 in skeletal muscle and infiltrated 
neutrophils in CRPS-I model in mice. Mice were subjected to I/R-induced CRPS-I (see 
Methods). Panel A: Immunofluorescence analysis were conducted in hind paws 
harvested at 49 h after reperfusion from disease animals or treated with HCE-CS (30 
mg/Kg p.o.) or BML-111 (1 µg, s.c.) at 10 min, 24 and 48 h after reperfusion. Panel B: 
Quantitative data for ALX/FPR2 are presented as mean ± S.E.M., n=8 (One-way 
ANOVA followed by Tukey’s test).  
 
Fig. 9. Absence of pannus or cartilage erosion in joints of hind paws during the 
inflammatory phase of CRPS-I model in mice. Mice were subjected to I/R-induced 
injury (see Methods). Histological analysis was conducted in hind paws harvested at 49 
h after reperfusion from sham animals or treated with HCE-CS (30 mg/Kg p.o.) or 
BML-111 (1 µg, s.c.) at 10 min, 24 and 48 h after reperfusion. In quantitative analysis 
data are presented as mean ± S.E.M., n=8 (One-way ANOVA followed by Tukey’s 
test).  
4. Discussion 
The present study demonstrated that HCE from the leaves of Casearia sylvestris 
displayed powerful anti-hyperalgesic effects during the inflammatory phase of 
experimental CRPS-I. These data also indicate, likely for the first time, an involvement 
of the mechanisms of the resolution of inflammation in the properties of the plant 
extract leading to the suggestion that both classes of compounds (HCE-CS and pro-
resolving mediators) can provide pharmacological tools for the treatment of this 
condition in humans. 
CRPS-I is a debilitating disease, with a complex clinical presentation which 
importantly includes disturbances in sensorial perception leading to severe pain 
(Coderre & Bennett, 2010). Our findings that HCE-CS and pro-resolving mediators can 
reduce mechanical hyperalgesia is particularly important given that both classes of 
compounds (phytochemicals and pro-resolving lipid mediators) afforded efficacy 
similar to dexamethasone. While this last substance, from the glucocorticoid class, can 
be useful in the therapeutic management of CRPS-I, adverse effects are very well 
documented especially after chronic treatment. On these bases, new phamacological 
tools that control symptoms during the course of CRPS-I are of need.  
With relation to possible mechanisms of action, it seems that this is the first 
study to evaluate contribution of resolution of inflammation pathways on 
antihyperalgesic effect exerted by an extract of plant. Chromatographic analysis of 
HCE-CS used in this study revealed the presence of several casearins including 
casearin-X, which was already implicated for its capability of coupling to GABA-A 
comples neuron receptors (de Araújo et al., 2017), what could influence pain 
phenomena. In the other hand, our results with the CRPS-I model demonstrate that a 
selective ALX/FPR2 antagonist (Shin et al., 2006), WRW4 prevented the 
antihyperalgesic action for HCE-CS or BML-111 implicating this receptor in 
modulatory mechanisms on nociception exerted by these treatments during the 
inflammatory phase of this experimental disease. These data unveil that HCE-CS and 
BMLL-111-induced overexpression of this receptor occurs locally, both in skeletal 
muscle and in neutrophils at the site of I/R injured tissue. However, this receptor is also 
expressed centrally (Abdelmoaty et al., 2013) hence we cannot exclude a priori a role 
for central ALX/FPR2 in these pharmacoligical effects reported here. Within the 
periphery, inflitrated neutrophils but not lymphocytes or macrophages could be 
quantified though the treatments did not alter their values. One could propose that the 
phenotype of the immune cells could have been changed by the anti-nociceptice 
treatments of which the higher expression of ALX/FPR2 could be the marker. We note 
how this receptor is over-expressed following TNF application as well as upon contril 
by endogenous TNF in sepsis (Gobtti et al., 2014). In human neutrophils, sex hormones 
promote an AnxA1+ALX/FPR2 phenotype (Nadkarni et al., 2011) which is associated 
with vascular protection (Nadkarni et al., 2014). It remains to be establish here what are 
the molecular determinants linking the plant extract and BML-111 to ALX/FPR2 over-
expression but the functional data indicate a relevant engagement of this receptor in the 
effects described herein.  
We propose that aside mast cells seems to contribute to CRPS-I (Huygen et al., 
2004), is reasonable that neutrophil infiltration to the muscle might have implications to 
the nociceptive process observed in the present study, with appearing of mechanical 
hyperalgesia in I/R-induced animal, since in humans decreased pressure pain threshold 
(muscle hyperalgesia) is one of the most proeminente sensory abnormalities observed 
(van Rooijen et al., 2013). Considering the present model of CPIP induced by I/R, these 
founds are also in agreement with the idea that targeting ALX/FPR2 receptors in both 
types of cells can be useful to treat symptoms of diseases in which pathophysiology 
relies importantly on vascular disturbances (Jones et al., 2016; Dufton & Perretti, 2010), 
specially those involving I/R-induced injuries (Gavins, 2010). 
In view of the number of ligands that can interact with ALX/FPR2 receptor, it 
could be hard to identify the endogenous agonist responsible for the antihyperalgesic 
effects observed here, though AnxA1 and LXA4 are obvious candidates. However, 
based on our behavioural experiments as well as on recent published studies, we can 
indicate LXA4 as the most likely mediator involved in these actions. Firstly, BML-111 
is a synthetic analog for LXA4 and it produced biological effects through interaction 
with the ALX/FPR2 receptor as reported in several systems (Sordi et al., 2013; Wu et 
al., 2016). Secondly, LXA4 levels are increased in mice in a model of I/R, specially 
after reperfusion stage, in which large amounts of neutrophil/platelet aggregates are 
formed (Brancaleone et al., 2013). In vitro, LXA4 exerts powerful tissue protective 
effects on rat cardiomyocites after I/R through up-regulation of heme oxygenase-1 
(Chen et al., 2013), downregulation of GRP-78 and caspase-12, as well as inhibition of 
cell apoptosis; while in vivo, the mediator was also beneficial to vascular smooth 
muscle cells in a mouse model of carotid artery ligation (Zhao et al., 2014). At variance 
from LXA4, our data exclude presence and functional involvement of AnxA1 since this 
protein was not particularly abundant at the site of injury and its absence in the knock 
out mice failed to influence mechanical hyperalgesia. This last result is in agreement 
with recently published, in which muscles in AnxA1-deficient mice were not affected in 
size or in repair of myofibers following application of different types of injuries 
(Leikina et al., 2015). 
Altogether these data allow us to speculate that during the inflammatory phase 
of a mouse CRPS-I model, ALX/FPR2 expressed in neutrophils and skeletal muscle is 
targeted by HCE-CS, directly or indirectly through endogenous LXA4 release (an effect 
mimicked by the pharmacological delivery of BML-111). Engagement of ALX/FPR2 
would in turn reduce mechanical hyperalgesia promoted by derangement in this tissue. 
Antihyperalgesic effect for LXA4 and its derivatives is very well documented in 
different animal models (Petri et al., 2015; Wang et al., 2014; Abdelmoaty et al., 2013). 
On other hand HCE-CS has already presented antinociceptive action (De Mattos et al., 
2007) and it can also evoke antiinflamatory and antioxidant properties (Albano et al., 
2013). 
Finally, regarding our present findings from histological analysis, besides other 
models of CRPS-I induced by nerve ligation (Li et al., 2013) or auto-immunity (Goebel 
& Blaes, 2013) have also been described, in the present study we used a model of 
CRPS-I caused by I/R wich faithfully reproduces human symptoms (Laferrière et al., 
2008). Currently, morphological alterations observed during CRPS-I is not related to 
nerve injury or bone alterations, specially during initial phases of the disease; however, 
changes in skin, specially in microcirculation, and muscle tissues have been found 
(Coderre & Bennett, 2010; Millecamps et al., 2010). In muscles, patients who have 
suffered amputation of the affected limb, presented major disturbances such as fatty 
degeneration, atrophy of fibers and nuclear agglomeration, not related to the duration of 
the syndrome, while extensor and flexor muscles of the forearm from other patients 
were affected as evaluated by ultrassonography (Goebel & Blaes, 2013; Vas et al., 
2013; Huang et al., 2011; Schürmann et al., 2007). This results are in accordance with 
our histological data demonstrating no alterations in cartilage nor pannus formation at 
the joints of animals from disease group while, in the contrary, skeletal muscle was 
massively surrounded by infiltration of inflammatory cells which, as expected, were not 
present in sham group. 
 
 
 
5. Conclusion  
We presented evidence that to demonstrate the involvement of a pathway of 
resolution of inflammation centred on LXA4 and the receptor ALX/FPR2 in the 
antihyperalgesic effect for HCE-CS and BML-111 during the inflammatory phase of 
CPIP model. These results also suggest a potential role for endogenous pro-resolving 
mediators in the pharmacological properties of Casearia sylvestris extract, a conclusion 
that may have dual implications with respect to innovative therapies for this debilitating 
conditions: i) use the extract as a novel treatment for CRPS-I in humans and ii) develop 
ALX/FPR2 agonists, likely modeled on LXA4, as novel scaffold for therapeutic 
development. 
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